<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1069308/000156459023003860/acer-8k_20230317.htm>Download 8-K Special Filing Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1069308/000156459023003860/0001564590-23-003860-index.htm>Original filing index</a>
                    </div>

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

Form 8-K - Current report - Item 8.01 Item 9.01

Acer Therapeutics Inc

Announcement: ACER 8-K Special Filing

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1069308/000156459023003612/acer-8k_20230315.htm>Download 8-K Special Filing Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1069308/000156459023003612/0001564590-23-003612-index.htm>Original filing index</a>
                    </div>

Analyst Summary:
Acer Therapeutics announced the presentation of data from a survey designed for the preferences of healthcare providers for Urea Cycle Disorders (UCDs) on March 19th at the 44th Annual Meeting of the Society for Inherited Metabolic Disorders. It sought to capture the perspectives of healthcare providers with experience treating UCDs to quantify the attributes of nitrogen-binding medications. OLPRUVA preliminary launch activities are progressing, with commercial and medical affairs teams built to support a U.S. launch in Q2 2023. The company also introduced OLPRUVA Navigator designed to help UCD patients with support, access, education, and patient adherence to treatment. The company plans to invest in additional solutions aimed at improving outcomes for UCD patients.
 
CEO Chris Schelling said, "We are proud that we can provide OLPRUVA™ -- an innovative, responsibly priced treatment option -- to patients with UCDs. And we are committed to working closely with the UCD community to ensure that those affected by this terrible disease live their lives with as few challenges and interruptions as possible."
 
Forward-looking statements are provided in the press release, including the availability of financing to fund pipeline product development programs and general corporate operations, risks related to drug development and the regulatory approval process, timing and requirements of regulatory actions, and the potential for continuity of Acer's pricing strategy  and related plans and expectations. 

$ACER Reports Launch Details for OLPRUVA and UCD Patient Support

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1069308/000110465923021878/tm236168d17_sc13ga.htm>Download SC 13G/A Special Filing</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1069308/000110465923021878/0001104659-23-021878-index.htm>Original filing index</a>
                    </div>

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Announcement: ACER SC 13G/A Statement of acquisition of beneficial ownership by individuals - amendment

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1069308/000156459023001755/acer-8k_20230213.htm>Download 8-K Special Filing Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1069308/000156459023001755/0001564590-23-001755-index.htm>Original filing index</a>
                    </div>

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1069308/000119312523026904/d435757d8k.htm>Download 8-K Special Filing Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1069308/000119312523026904/0001193125-23-026904-index.htm>Original filing index</a>
                    </div>

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1069308/000156459023001293/acer-8k_20230201.htm>Download 8-K Special Filing Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1069308/000156459023001293/0001564590-23-001293-index.htm>Original filing index</a>
                    </div>

Form 8-K - Current report - Item 7.01 Item 9.01